|Ms. Jennifer Chow||CEO, MD & Director||1.23M||N/A||N/A|
|Dr. Li Ren||VP of Technical Operations||N/A||N/A||N/A|
|Mr. Eliot Bourk||Chief Bus. Officer & Head of External Innovation||N/A||N/A||N/A|
|Mr. Kelly R. Thornburg||VP & Head of Quality||N/A||N/A||1963|
|Mr. Jason B. Litten M.D.||Chief Medical Officer||N/A||N/A||1974|
|Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA||Sec.||N/A||N/A||1961|
|Mr. Nathan Jong C.A.||Company Sec.||N/A||N/A||N/A|
Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is in Phase I clinical study for Glioblastoma; and CDH17 CAR T, which is in preclinical study for neuroendocrine tumours, as well as colorectal, pancreatic, and gastric cancer. It has a strategic partnership with OncoBay Clinical for the development program of CLTX CAR T. The company was incorporated in 2020 and is based in Carlton, Australia.
Chimeric Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.